Oncotarget

February 19, 2019

View Archive »

About The Cover

The cover for issue 15 of Oncotarget features Figure 6, "A schematic diagram illustrating the likely mechanism(s) of the TSPX-mediated suppression of the MYC gene," by Kido, et al.

Table of Contents

Research Papers

mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development

mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development

https://doi.org/10.18632/oncotarget.26668

Laura Molina, Hong Yang, Adeola O. Adebayo Michael, Michael Oertel, Aaron Bell, Sucha Singh, Xin Chen, Junyan Tao,  and Satdarshan P.S. Monga
1475-1490
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner

The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner

https://doi.org/10.18632/oncotarget.26673

Tatsuo Kido, Yunmin Li, Yuichiro Tanaka, Rajvir Dahiya,  and Yun-Fai Chris Lau
1491-1506
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma

https://doi.org/10.18632/oncotarget.26682

Sandy Tretbar, Peter Krausbeck, Anja Müller, Michael Friedrich, Christoforos Vaxevanis, Juergen Bukur, Simon Jasinski-Bergner,  and Barbara Seliger
1507-1524
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

POPX2 is a novel LATS phosphatase that regulates the Hippo pathway

POPX2 is a novel LATS phosphatase that regulates the Hippo pathway

https://doi.org/10.18632/oncotarget.26689

Muhammad Bakhait Rahmat, Songjing Zhang,  and Cheng-Gee Koh
1525-1538
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Corrections

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy

https://doi.org/10.18632/oncotarget.26723

Jian Cui, Lin Yang, Lei Guo, Yongfu Shao, Dongfeng Tan, Ni Li,  and Haizeng Zhang
1539-1539
Correction  |  PDF  |  How to cite


Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC